Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2017 Nov 28;7(11):e017733.
doi: 10.1136/bmjopen-2017-017733.

Viability testing and transplantation of marginal livers (VITTAL) using normothermic machine perfusion: study protocol for an open-label, non-randomised, prospective, single-arm trial

Richard W Laing  1   2 , Hynek Mergental  1   2 , Christina Yap  3 , Amanda Kirkham  3 , Manpreet Whilku  3 , Darren Barton  3 , Stuart Curbishley  2 , Yuri L Boteon  1   2 , Desley A Neil  1 , Stefan G Hübscher  1   2 , M Thamara P R Perera  1   2 , Paolo Muiesan  1   2 , John Isaac  1 , Keith J Roberts  1 , Hentie Cilliers  1 , Simon C Afford  2 , Darius F Mirza  1   2
Affiliations

Viability testing and transplantation of marginal livers (VITTAL) using normothermic machine perfusion: study protocol for an open-label, non-randomised, prospective, single-arm trial

Richard W Laing et al. BMJ Open. .

Abstract

Introduction: The use of marginal or extended criteria donor livers is increasing. These organs carry a greater risk of initial dysfunction and early failure, as well as inferior long-term outcomes. As such, many are rejected due to a perceived risk of use and use varies widely between centres. Ex situ normothermic machine perfusion of the liver (NMP-L) may enable the safe transplantation of organs that meet defined objective criteria denoting their high-risk status and are currently being declined for use by all the UK transplant centres.

Methods and analysis: Viability testing and transplantation of marginal livers is an open-label, non-randomised, prospective, single-arm trial designed to determine whether currently unused donor livers can be salvaged and safely transplanted with equivalent outcomes in terms of patient survival. The procured rejected livers must meet predefined criteria that objectively denote their marginal condition. The liver is subjected to NMP-L following a period of static cold storage. Organs metabolising lactate to ≤2.5 mmol/L within 4 hours of the perfusion commencing in combination with two or more of the following parameters-bile production, metabolism of glucose, a hepatic arterial flow rate ≥150 mL/min and a portal venous flow rate ≥500 mL/min, a pH ≥7.30 and/or maintain a homogeneous perfusion-will be considered viable and transplanted into a suitable consented recipient. The coprimary outcome measures are the success rate of NMP-L to produce a transplantable organ and 90-day patient post-transplant survival.

Ethics and dissemination: The protocol was approved by the National Research Ethics Service (London-Dulwich Research Ethics Committee, 16/LO/1056), the Medicines and Healthcare Products Regulatory Agency and is endorsed by the National Health Service Blood and Transplant Research, Innovation and Novel Technologies Advisory Group. The findings of this trial will be disseminated through national and international presentations and peer-reviewed publications.

Trial registration number: NCT02740608; Pre-results.

Keywords: hepatobiliary disease; hepatobiliary tumours; hepatology; transplant surgery.

PubMed Disclaimer

Conflict of interest statement

Competing interests: RWL and YB receive salary as Wellcome Trust research fellows.

Figures

Figure 1
Figure 1
Patient and donor liver pathways. HA, hepatic artery; PV, portal vein; UHB, University Hospitals Birmingham; VITTAL, Viability testing and transplantation of marginal livers.
Figure 2
Figure 2
Trial schema. VITTAL, Viability testing and transplantation of marginal livers.
See this image and copyright information in PMC

References

    1. Williams R, Aspinall R, Bellis M, et al. Addressing liver disease in the UK: a blueprint for attaining excellence in health care and reducing premature mortality from lifestyle issues of excess consumption of alcohol, obesity, and viral hepatitis. Lancet 2014;384:1953–97. 10.1016/S0140-6736(14)61838-9 - DOI - PubMed
    1. Williams R, Ashton K, Aspinall R, et al. Implementation of the lancet standing commission on liver disease in the UK. Lancet 2015;386:2098–111. 10.1016/S0140-6736(15)00680-7 - DOI - PubMed
    1. Mathur AK, Ranney DN, Patel SP, et al. The effect of smoking on biliary complications following liver transplantation. Transpl Int 2011;24:58–66. 10.1111/j.1432-2277.2010.01146.x - DOI - PubMed
    1. NHS Blood and Transplant. Organ Donation and Transplantation Activity Report 2015/2016;16.
    1. NHS Blood and Transplant. Annual report on liver transplanation 2015/2016;16.

Associated data